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Atrial ﬁbrillation is a common clinical disease especially in the elderly and in patients with organic heart disease. Electrical
cardioversion is the ﬁrst choice therapeutic approach for patients in which sinus rhythm could improve the quality of life and
where the maintenance of sinus rhythm is considered likely. There are diﬀerent techniques to perform an electrical cardioversion,
each with speciﬁc indications, advantages, and limitations. The method most frequently used to restore sinus rhythm is external
direct current cardioversion; however, this technique has some disadvantages, since it requires a high energy and usually general
anesthesia. Esophageal cardioversion is an alternative method to obtain restoration of sinus rhythm, warranting acute and long-
termresultsabsolutelycomparablewiththoseobtainedbytheconventionaltransthoracictechnique,especiallyinobeseandCOPD
patients with high thoracic impedance for whom the standard technique may be less eﬀective.
1.Introduction
Atrial ﬁbrillation is a common clinical disease especially in
the elderly (3–5% of the population over 60 years), and in
patients with organic heart disease (70–80%) [1].
Electrical cardioversion (ECV) is the ﬁrst-choice thera-
peutic approach for patients in which sinus rhythm could
improve the quality of life and where the maintenance of
sinus rhythm is considered likely. This technique compared
with pharmacological cardioversion shows some important
advantages: immediate eﬀect, high success rate, and safety in
hemodynamically unstable patients.
There are three main groups of patients in whom sinus
rhythm is a beneﬁt:
(i) patients with severe symptoms during the arrhyth-
mia,
(ii) patients with recent-onset atrial ﬁbrillation in order
to prevent electrical remodeling,
(iii) patients with structural heart disease, such as hyper-
tension and ventricular hypertrophy, which can
achieve a signiﬁcant hemodynamic improvement by
restoring sinus rhythm.
There are several techniques to perform an electrical car-
dioversion, each with speciﬁc indications, advantages, and
limitations. The method most often used to restore sinus
rhythm is the external direct current cardioversion; however,
this technique has some disadvantages, since it requires a
high energy and usually general anesthesia.
2.Esophageal ElectricalCardioversion
This type of cardioversion may overcome some limitations
of the standard external cardioversion. In some patients,
the high thoracic impedance, due to emphysema or to
a high body surface, changes the transmission of direct
currentshockthroughthethoraxandrepresentsasigniﬁcant
predictor of failure of external cardioversion [2]. Esophageal
cardioversion provides several advantages such as the follow-
ing:
(i) a lower energy requirement thanks to closeness of
the esophagus with the left atrium which warrants
a lower energy dispersion and a lower deﬁbrillation
impedance. When we give a direct current shock,
using an external conﬁguration, only around 20% of
energy delivered reaches the heart, because most of2 Cardiology Research and Practice
Figure 1: Decapolar catheter Esoﬂex, FIAB, Vicchio, FI, Italy.
Figure 2: Esophageal-precordial conﬁguration.
the energy is dispersed in noncardiac tissues, espe-
cially in high-thoracic impedance patients [3];
(ii) avoidance of general anaesthesia or deep sedation: as
low energies are required, a mild sedation is suﬃcient
to make the procedure well tolerated by most of the
patients;
(iii) safety in patients with pacemaker or ICD: there
is a lower risk of damage and of increasing the
pacing threshold, which is a phenomenon related to
shock intensity, especially dangerous for pacemaker-
dependent patients [4];
(iv) availability of atrial pacing backup: the esophageal
catheter may also be used to stimulate the atrium
in case of a prolonged postshock sinus arrest, sinus
bradycardia, or a pacemaker exit block.
The technique used in the most recent studies about eso-
phagealcardioversionistheesophageal-precordialcardiover-
sion. In this conﬁguration, energy is applied between the
electrodes of an esophageal decapolar polyurethane catheter
(5.7cm2 total electrode surface, Esoﬂex, FIAB, Vicchio, FI,
Italy) as cathode (Figure 1) and one or two precordial
adhesive patch electrodes as anode. Such a conﬁguration
provides a greater electrode surface and embraces a larger
area of atrial tissue (Figure 2). This conﬁguration generates
a uniform electric ﬁeld during the shock which results in
vectors with a low atrial deﬁbrillation threshold.
Many studies, in more than 40 years of esophageal
cardioversion, have proven safety of such technique, per-
forming even histological examination of the esophageal
mucosa in the animals underwent to esophageal shocks
[5] or esophageal endoscopy in patients underwent to the
esophageal-intracardiac cardioversion [6]. McKeown et al.
[7] showed that no damage or dysphagia was seen in patients
receiving shocks less than 100 joules.
Esophagealcardioversionishighlyeﬀective(95.3%).Fur-
thermore, using 50J or less, the 88.5% of the patients may be
cardioverted [8].
The method is quite simple and very fast, and the only
criterion used to assess the good position of the catheter
can be the length of the catheter’s part introduced into the
esophagus (40–45cm from the nostril), without any need of
radioscopiccontrolneitherofrecordingtheesophagealECG.
The sedation may be obtained by diﬀerent drugs, the most
used is midazolam, which is eﬀective at low dosage, safe, and
handy. Finally, this technique showed to be well tolerated
by patients and could be easily performed in an outpatient
regimen.
Recently, our group has compared the external electrical
cardioversion and the esophageal one, both under a con-
scious sedation by midazolam. The conclusions were that
the outpatient cardioversion of AF may be performed safely
and eﬀectively by either a transthoracic or a transesophageal
approach.TherateofearlyrecurrenceofAFbeforetheendof
sedation did not show any signiﬁcant diﬀerence between the
twogroups,andasecondECVwaseﬀectiveinallthepatients
[9]. As transesophageal ECV shows no clear advantage,
transthoracic cardioversion should remain the approach of
ﬁrst choice, due to the economical issues and to the lowest
complexity.
Nevertheless, esophageal cardioversion may still play an
important role in selected patients such as obese or COPD
patients with high thoracic impedance.
A particular further advantage in the use of the trans-
esophageal approach for the ECV could be the possibility
to use a probe which combines the echocardiographic im-
aging capabilities of a probe in the esophagus with the
cardioverting abilities. Two publications have outlined this
approach [10, 11]. In these two papers, authors showed
as a custom-made probe, for combined TEE plus TEC,
oﬀered an eﬀective early cardioversion with low energy levels
after exclusion of a clot. The procedure was well tolerated,
and even hemodynamics could be monitored during and
immediately after cardioversion. These two papers show
how, with such an approach, it could be possible to perform
inauniquesteptwoproceduresthatatpresentarenecessarily
performed through two separate steps: ﬁrst, the exclusion, by
a TEE probe, of the presence of a left atrial thrombus and
then the execution, by the same probe introduced into the
oesophagusoftheelectricalcardioversion.Suchanapproach,
of course, would have the clear advantage to be time saving
and cost eﬀective.
3. Conclusions
There are diﬀerent techniques to perform an electrical car-
dioversion, each with speciﬁc indications, advantages, and
limitations. The method most frequently used to restoreCardiology Research and Practice 3
sinus rhythm is the external cardioversion, which showed to
be a safe, eﬀective, and well-tolerated technique even avoid-
ing general anaesthesia or deep sedation, especially now
that biphasic waveform deﬁbrillators are widely available
[9, 12, 13]. Nevertheless, the esophageal cardioversion may
still play an important role in obese and COPD patients with
high thoracic impedance for which the external one may be
less eﬀective. A very promising application for esophageal
electrical cardioversion could arise from the possibility to
use a probe assembled for simultaneous transesophageal
echocardiography and transesophageal cardioversion [10,
11]. The use of such a combined probe may be the technique
of choice for patients who require both cardioversion and
transesophageal echocardiography.
Therefore, esophagus comes again to help cardiologists
as it does, on a routine basis, since more than 20 years
through the transesophageal echocardiography [14, 15]o r
the transesophageal electrophysiological study [16], oﬀering
them an alternative, safe, and very eﬀective technique to per-
form electrical cardioversion and restore sinus rhythm.
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